Absin IHC Kit Facilitates Key Discoveries in Osteosarcoma Cisplatin Resistance Research

In the field of cancer treatment, osteosarcoma, as the most common primary malignant bone tumor in children and adolescents, has long been limited by cisplatin (DDP) resistance in its treatment. Recently, a team from the Second Xiangya Hospital of Central South University published the paper PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma in Signal Transduction and Targeted Therapy (IF=52.7). This study is the first to reveal the molecular mechanism by which PKMYT1 kinase mediates cisplatin resistance in osteosarcoma through regulating NPM1 phosphorylation, providing a new therapeutic target for solving the problem of drug resistance. In this groundbreaking research, Absin's ready-to-use high-efficiency immunohistochemical secondary antibody kit (Catalog No.: abs957) supported the accurate detection of key proteins in tissue samples throughout the process, laying a solid histological foundation for the research conclusions.

 
Research Background: The "Drug Resistance Dilemma" in Osteosarcoma Treatment
 
Although the 5-year survival rate of osteosarcoma patients has increased to 60%-70%, cisplatin resistance remains the main cause of treatment failure. Statistics show that most patients develop acquired resistance during chemotherapy, leading to tumor recurrence or metastasis, and the 5-year survival rate drops sharply to 20%. Therefore, exploring the mechanism of drug resistance and identifying targets to reverse drug resistance have become key focuses of scientific research.
 
Through whole-genome CRISPR screening combined with transcriptome sequencing, this study identified PKMYT1 as a key kinase regulating cisplatin sensitivity, and further clarified the molecular pathway by which it phosphorylates the S260 site of NPM1, competitively inhibits NPM1 SUMOylation, and ultimately affects the recruitment of DNA damage repair proteins (BRCA1, RAP80, RAD51). The verification of this series of mechanisms relied on the accurate detection of protein expression in tissue samples—and Absin's IHC detection kit played a crucial role here.
 
The Launch of Absin's Core Product: High-Efficiency IHC Detection Kit (abs957)
 
In the research, the team needed to use immunohistochemistry (IHC) technology to verify the expression changes of proteins such as PKMYT1 and NPM1-S260 in osteosarcoma tissues, especially the analysis of differences and correlations before and after chemotherapy. The experiment adopted the Absin High-Efficiency IHC Detection System Kit (Catalog No.: abs957), which, with its advantages of high sensitivity and low background, became a "reliable assistant" for tissue protein detection.
 
Detection of PKMYT1 Expression Differences Before and After Chemotherapy
 
The study found that cisplatin treatment can induce the activation of PKMYT1 in osteosarcoma cells, and the IHC results are an important support for this conclusion. The team used the Absin abs957 kit to detect tissue samples from 20 osteosarcoma patients before and after chemotherapy, and the results clearly showed that the expression of PKMYT1 in tissues after chemotherapy was significantly higher than that before chemotherapy (Fig. 1j), directly confirming the correlation between cisplatin and PKMYT1 activation.
 

 

 
✦ Verification of the Correlation Between NPM1-S260 and PKMYT1
 
In the mechanism research, the team found that PKMYT1 can specifically phosphorylate the S260 site of NPM1, and the phosphorylation level is positively correlated with the expression of PKMYT1. Detection of 29 osteosarcoma tissue samples using the Absin IHC kit confirmed the high expression of NPM1-S260 in tumor tissues, and it showed a significant positive correlation with PKMYT1 expression (Spearman r=0.7615, P<0.001, Fig. 3n), providing direct histological evidence for the "PKMYT1-NPM1" regulatory axis.
 
✦ Detection of Tumor Proliferation Marker Ki67
 
In animal experiments, the team detected the expression of Ki67 in tumor tissues through IHC to evaluate the inhibitory effect of PKMYT1 knockout combined with cisplatin on tumor proliferation. The Absin kit clearly showed that the proportion of Ki67-positive cells in the PKMYT1 knockout + cisplatin group was significantly reduced (Fig. 2n, 4n), directly verifying the anti-proliferative effect of the combined treatment.

 
Why Choose the Absin abs957 IHC Kit?
 
As a key tool supporting high-impact papers, the Absin High-Efficiency IHC Detection System Kit has three core advantages:
 
 
✦ High Sensitivity: It can accurately detect low-abundance proteins (such as the phosphorylated modified protein NPM1-S260), ensuring no omission of weak signals;
✦ Low Background Interference: Through an optimized secondary antibody system and chromogenic protocol, non-specific staining is reduced, making the results more clear and reliable;
✦ Convenient Operation: The kit contains a complete set of reagents (blocking solution, primary antibody dilution buffer, HRP-labeled secondary antibody, DAB chromogenic solution, etc.), no additional preparation is required, and the experimental process is more efficient.
 
Just as in this study, from clinical tissues to animal models, the Absin abs957 kit stably produced high-quality IHC results throughout the process, providing strong support for the complete evidence chain from clinical samples to mechanism verification.
 
Related products：
 

Catalog	Product Name	Specification
abs957	Ready to use high-efficiency immunohistochemical secondary antibody kit	5mL
abs996	Ready to use immunohistochemical secondary antibody kit (anti rabbit&mouse)	5mL
abs998	Ready to use immunohistochemical secondary antibody kit (anti rabbit)	5mL
abs997	Ready to use immunohistochemical secondary antibody kit (anti mouse)	5mL